Introduction

Low-dose naltrexone (LDN) has gained attention within the Lyme disease community as a potential complementary therapy for managing certain chronic symptoms. While standard treatment for Lyme disease typically involves antibiotics when appropriate, some individuals living with persistent symptoms continue to explore supportive approaches that may help improve their overall quality of life.

LDN is a much lower dose of naltrexone than the medication traditionally used to treat opioid and alcohol dependence. Researchers have been investigating whether low-dose naltrexone may influence the immune system, reduce inflammation, and affect pain processing. These potential effects have led to growing interest in its possible role for conditions involving chronic pain, autoimmune diseases, fibromyalgia, multiple sclerosis, and post-treatment Lyme disease symptoms (PTLDS).

However, an important question remains: What does research say about LDN for Lyme disease? At present, scientific evidence specifically evaluating LDN in people with Lyme disease is limited. While laboratory studies and research involving other inflammatory conditions provide valuable insights, more high-quality clinical trials are needed before firm conclusions can be made regarding its effectiveness for Lyme disease.

In this educational article from Holistic Therapy TribeLDN and Lyme Disease, we review the current evidence, explain how LDN is thought to work, discuss ongoing research, and explore why healthcare providers emphasize individualized medical guidance when considering complementary therapies.

What Is Low-Dose Naltrexone (LDN)?

Low-dose naltrexone is an off-label use of the medication naltrexone.

Traditional naltrexone is commonly prescribed at much higher doses for substance use disorders.

LDN typically refers to significantly lower doses that researchers have investigated for various inflammatory and immune-related conditions.

Unlike standard Lyme disease treatments that directly target Borrelia burgdorferi, LDN is not an antibiotic and is not approved specifically for treating Lyme disease.

Instead, researchers are studying whether it may influence biological pathways involved in:

• Inflammation
• Immune regulation
• Pain signaling
• Endorphin production
• Nervous system activity

Why Has LDN Become a Topic of Interest in Lyme Disease?

Many individuals living with Lyme disease experience symptoms such as:

• Fatigue
• Joint pain
• Muscle aches
• Sleep disturbances
• Neurological symptoms
• Cognitive difficulties
• Ongoing inflammation

Some of these symptoms may persist in a subset of patients even after recommended antibiotic treatment, a condition often referred to as Post-Treatment Lyme Disease Symptoms (PTLDS).

Because LDN has been investigated in other chronic inflammatory conditions, researchers have questioned whether similar biological mechanisms might be relevant in Lyme disease.

However, current research remains limited.

How Is LDN Thought to Work?

Although researchers continue studying LDN, several possible mechanisms have been proposed.

Temporary Opioid Receptor Blockade

One leading theory suggests that temporarily blocking opioid receptors may encourage the body to increase production of naturally occurring endorphins.

Endorphins play important roles in:

• Pain regulation
• Mood
• Stress responses
• Immune signaling

Researchers continue evaluating how these changes may influence chronic inflammatory conditions.

Immune System Modulation

Another area of research focuses on immune regulation.

Rather than broadly suppressing the immune system, some laboratory studies suggest LDN may help influence immune cell activity and inflammatory signaling.

Scientists continue investigating whether this effect could have relevance for chronic inflammatory disorders.

Microglial Cell Activity

One of the most discussed research areas involves microglia, specialized immune cells located within the central nervous system.

When activated for prolonged periods, microglia may contribute to:

• Persistent inflammation
• Pain sensitivity
• Fatigue
• Neurological symptoms

Some experimental studies suggest LDN and Lyme Disease may influence microglial activation, although researchers emphasize that additional human studies are needed.

What Does Current Research Actually Show?

This is one of the most important questions.

At present, there are relatively few high-quality clinical studies specifically evaluating LDN for Lyme disease.

Instead, much of the available information comes from:

• Small observational studies
• Case reports
• Laboratory research
• Studies involving other chronic illnesses
• Patient-reported experiences

While these sources generate valuable hypotheses, they do not provide the same level of evidence as large randomized controlled trials.

What Have Studies in Other Conditions Found?

Although Lyme-specific studies are scarce, LDN has been investigated in several other conditions.

These include:

Fibromyalgia

Some small clinical studies have reported improvements in pain and quality of life among certain individuals with fibromyalgia.

Researchers believe immune regulation and reduced neuroinflammation may contribute, but additional research remains necessary.

Multiple Sclerosis

LDN has also been studied in multiple sclerosis.

Some research has focused on:

• Fatigue
• Quality of life
• Symptom management

Results have been mixed, and researchers continue investigating its potential role.

Crohn's Disease

Several studies have examined LDN in inflammatory bowel disease.

Researchers observed possible improvements in disease activity in some patients, although larger trials are still recommended.

Because inflammation plays a role in many chronic illnesses, these studies have contributed to broader scientific interest in LDN.

However, findings from other diseases cannot automatically be applied to Lyme disease.

Is There Evidence That LDN Reduces Lyme Disease Symptoms?

Currently, there is no strong clinical evidence proving that LDN directly treats Lyme disease or eliminates Borrelia burgdorferi.

Instead, researchers are exploring whether LDN might have a role in managing certain symptoms that may persist in some individuals.

Potential areas being studied include:

• Chronic pain
• Fatigue
• Sleep quality
• Inflammation
• Neurological symptoms
• Overall quality of life

These investigations remain ongoing, and evidence is still considered preliminary.

Is LDN Approved for Lyme Disease?

No.

LDN is not approved by the U.S. Food and Drug Administration (FDA) specifically for Lyme disease.

When prescribed for Lyme disease-related symptoms, it is considered an off-label medication.

Off-label prescribing is common in medicine but requires careful discussion between patients and qualified healthcare professionals regarding:

• Potential benefits
• Possible risks
• Current scientific evidence
• Individual medical history
• Medication interaction